DBV Technologies (DBVT) Restructuring Costs (2020 - 2021)
DBV Technologies (DBVT) reported Restructuring Costs of $438000.0 for Q4 2021, down 82.82% year-over-year from $2.5 million in Q4 2020, and down 82.82% on a QoQ basis from $2.5 million in Q4 2020.
DBV Technologies (DBVT) has 2 years of Restructuring Costs data on file, last reported at $438000.0 in Q4 2021.
- Quarterly Restructuring Costs fell 82.82% year-over-year to $438000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $438000.0 (changed N/A YoY) and the FY2021 annual result came in at $438000.0, down 95.33% from the prior year.
- Restructuring Costs retreated to $438000.0 in Q4 2021 per DBVT's latest filing, from $2.5 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $21.3 million in Q2 2020 and bottomed at -$286000.0 in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 438,000.00 |
| Dec 31, 2020 | 2.55 Mn |
| Sep 30, 2020 | -286,000.00 |
| Jun 30, 2020 | 21.29 Mn |